At Optos, our vision is to be THE retina company and to be recognized as a leading provider of devices to eyecare professionals for improved patient care. In 2000, we delivered the first and only retinal imaging device that could capture 200° or 82% of the retina (optomap images). The ability to clearly image that much of the retina — in one capture, and in less than one second — significantly influences the way eyecare professionals can examine their patients’ eyes. An optomap image provides a bigger picture and more clinical information, which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.
Our Daytona and California devices have much smaller footprints that offer more imaging modalities in one device than any other retinal imaging device on the market. Color, red-free and autofluorescence imaging modalities are included in both devices. California features fluorescein angiography and our newest ultra-widefield imaging modality, indocyanine green angiography.
In addition, the image capture and viewing software is considered technically superior according to a number of doctors. When optomap images are viewed, they are an anatomically correct representation of the retina. This is expected with a standard fundus image (10%-45% of the retina). However, when 82% of the retina is imaged, shape bias (like the “Greenland Effect”) must be accounted for. Our technology presents optomap images in a consistent geometry that accurately represents anatomical features in the retina.
Optos is committed to utilizing the latest technology to manufacture new products and develop software that support optomap as a standard of care thereby helping eyecare professionals around the world save sight and lives. Furthermore, the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging as much of the retina as possible.
Information for this Industry Spotlight was supplied by Optos and not independently verified by Eye on Education.